Abstract: Disclosed are compositions and methods for treating benzodiazepine misuse and/or use disorder. A method of treating benzodiazepine misuse and/or use disorder includes administering to a subject in need thereof of an effective amount of a compound provides both partial modulator and antagonist effects at GABAA receptors.

Abstract: A method for treating or reducing a likelihood of hypoxia-ischemia induced brain damage and neurobehavioral dysfunction in neonates utilizes a relative high dose of nasally administered insulin. In one aspect, the method includes intranasally administering, to a neonate in need thereof, an effective dose of insulin comprising between 350 U to 2000 U insulin.

Abstract: Embodiments of the presently-disclosed subject matter include methods and systems for measuring a level of a neurotransmitter in a subject. Embodiments of the present methods comprise displaying a fixation point, a reward target, and a non-reward target, and measuring one or more saccade movement parameters for reward saccades and non-reward saccades. The saccade movement parameters can include velocity, amplitude, reaction time, or a combination thereof. The present methods can further include determining a reward modulation of the subject, the reward modulation being equal to a difference between the reward and the non-reward values for a respective saccade movement parameter. Some embodiments further include identifying the subject as including a deficiency of the neurotransmitter if there is a statistically measurable difference between the reward modulation of the subject and a reference reward modulation and/or if the non-reward and the reward saccade movement parameters are statistically equivalent.

Abstract: A renal cortex targeting elastin-like polypeptide (ELP), a renal medulla and cortex targeting ELP, and a method of treating a renal disorder are provided. The renal cortex targeting ELP includes up to 95 repeat units having the sequence VPGXG (SEQ ID NO: 1), where X in each of the repeat units is any amino acid except proline. The renal medulla and cortex targeting ELP includes at least 95 repeat units of SEQ ID NO: 1, where X in each of the repeat units is any amino acid except proline. The method of treating a renal disorder includes administering an ELP and a therapeutic drug to a subject in need thereof, where the ELP includes up to 671 repeat units of SEQ ID NO: 1 and X in each of the repeat units is any amino acid except proline.

Abstract: A method for administration of citrulline for the treatment of sickle cell disease and other complications of sickle cell disease thereof.

Abstract: A renal cortex targeting elastin-like polypeptide (ELP), a renal medulla and cortex targeting ELP, and a method of treating a renal disorder are provided. The renal cortex targeting ELP includes up to 95 repeat units having the sequence VPGXG (SEQ ID NO: 1), where X in each of the repeat units is any amino acid except proline. The renal medulla and cortex targeting ELP includes at least 95 repeat units of SEQ ID NO: 1, where X in each of the repeat units is any amino acid except proline. The method of treating a renal disorder includes administering an ELP and a therapeutic drug to a subject in need thereof, where the ELP includes up to 671 repeat units of SEQ ID NO: 1 and X in each of the repeat units is any amino acid except proline.

Abstract: Provided herein is technology relating to treatment of sepsis and particularly, but not exclusively, to methods for predicting a response of a sepsis patient to treatment with L-carnitine.

Abstract: A composition including an elastin-like polypeptide (ELP) coupled to a kidney targeting peptide and. a therapeutic agent is provided. A method of delivering a therapeutic agent to a subject in need thereof comprising: administering to the subject an effective amount of a composition comprising: an elastin-like polypeptide (ELP), a kidney targeting agent coupled to the ELP and a targeting agent and/or a drug binding domain coupled to the ELP, wherein the ELP includes an amino acid sequence having at least about repeats of the amino acid sequence GVPGX (SEQ ID NO: 1), and wherein the composition enhances the deposition and retention of the therapeutic agent in the kidney relative to the non-conjugated therapeutic.

Abstract: This invention relates to methods for ascertaining at least one of liver fibrosis or cirrhosis in a subject, by processing of one or more medical images of the liver, using a computing machine, to quantify nodularity of the surface of the liver and calculate a liver surface nodularity score.

Abstract: A composition including an elastin-like polypeptide (ELP) coupled to a therapeutic agent is provided. The ELP comprises at least about 5 repeats of the amino acid sequence VPGXG. Further provided is a method of using the composition for therapeutic agent delivery during pregnancy to reduce the amount of the therapeutic agent crossing a placenta in a pregnant subject. The method includes administering to the pregnant subject an effective amount of the composition comprising the ELP coupled to the therapeutic agent.

Abstract: A composition including an elastin-like polypeptide (ELP) coupled to a kidney targeting peptide and. a therapeutic agent is provided. A method of delivering a therapeutic agent to a subject in need thereof comprising: administering to the subject an effective amount of a composition comprising: an elastin-like polypeptide (ELP), a kidney targeting agent coupled to the ELP and a targeting agent and/or a drug binding domain coupled to the ELP, wherein the ELP includes an amino acid sequence having at least about repeats of the amino acid sequence GVPGX (SEQ ID NO: 1), and wherein the composition enhances the deposition and retention of the therapeutic agent in the kidney relative to the non-conjugated therapeutic.

Abstract: The present disclosure provides methods for colorizing and/or standardizing a medical image, comprising, for example, the steps of (i) receiving, in an image processing unit, digital image data obtained by an image capture device, wherein the digital image data includes a medical image; (ii) analyzing the data with the image processing unit to identify a region of interest; (iii) segmenting said region of interest; (iv) obtaining a measure of the pixel intensities in the segmented region of interest; (v) selecting an optimized color spectrum from a plurality of color spectra using the result of the measure of the pixel intensities in the segmented region of interest; (vi) colorizing the digital image data by mapping the selected color spectrum to the region of interest; and (vii) displaying the colorized medical image.

Abstract: A compound including a cell penetrating peptide (CPP) and elastin-like polypeptide (ELP), and a method for use thereof, are useful for inhibiting the proliferation of cancer.

Abstract: The present disclosure relates to peptides for treating cancer, wherein the peptides suppress BRCA1-IRIS expression or activity. The peptides may include an amino acid sequence as set forth in SEQ ID NO: 1 and/or SEQ ID NO: 2. Further, the present disclosure provides methods for treating cancer, wherein the cancer may be breast or ovarian cancer, including administering one of said peptides to a subject in need thereof.

Abstract: The present disclosure relates to peptides for treating cancer, wherein the peptides suppress BRCA1-IRIS expression or activity. The peptides may include an amino acid sequence as set forth in SEQ ID NO: 1 and/or SEQ ID NO: 2. Further, the present disclosure provides methods for treating cancer, wherein the cancer may be breast or ovarian cancer, including administering one of said peptides to a subject in need thereof.

Abstract: Methods for diagnosis and treatment of a cancer treatable with a c-Abl inhibitor are provided. Methods for diagnosing a cancer treatable with a c-Abl inhibitor include providing a biological sample from subject, determining an amount in the sample of geminin, c-Abl, or both, and comparing the amount of geminin, c-Abl, or both, if present, to a control level to thereby diagnose a subject as having a cancer treatable with a c-Abl inhibitor if there is a measurable difference in the amount of geminin, c-Abl, or both in the sample as compared to the control level. Methods for treating a cancer include identifying a subject as having a cancer treatable with a c-Abl inhibitor by determining an amount of geminin, c-Abl, or both, and then administering an effective amount of a c-Abl inhibitor to the subject. Screening methods for identifying compounds useful for inhibiting c-Abl are also provided.

Abstract: Aspects of the present invention include methods for inhibiting damage to a mammalian cornea, comprising administering an effective ?-toxin inhibiting about of a composition that comprises a ?-cyclodextrin and cholesterol.

Abstract: Embodiments of the presently-disclosed subject matter include methods and systems for measuring a level of a neurotransmitter in a subject. Embodiments of the present methods comprise displaying a fixation point, a reward target, and a non-reward target, and measuring one or more saccade movement parameters for reward saccades and non-reward saccades. The saccade movement parameters can include velocity, amplitude, reaction time, or a combination thereof. The present methods can further include determining a reward modulation of the subject, the reward modulation being equal to a difference between the reward and the non-reward values for a respective saccade movement parameter. Some embodiments further include identifying the subject as including a deficiency of the neurotransmitter if there is a statistically measurable difference between the reward modulation of the subject and a reference reward modulation and/or if the non-reward and the reward saccade movement parameters are statistically equivalent.

Abstract: A diagnostic method and predictor of prognosis from various therapeutic treatments is provided using discriminant analysis statistics. In one form, a patient is identified as having a disease using discriminant analysis when one or more values of a physiological parameter of the patient is closer to that of a previously characterized group of individuals having a disease and the patient is diagnosed as not having the disease, or healthy, if the value of a patient's parameter is closer to that of individuals previously characterized as healthy, or not having the disease. For example, the parameters can be based on the autonomic and/or enteric nervous system. Advantageously, the present method can be readily adapted using conventional linear discriminant analysis statistics to factor more than one parameter between a patient and one or more previously classified groups, to thereby enhance predictability and reliability of the present method.

Abstract: A compound including a cell penetrating peptide (CPP), an elastin-like polypeptide (ELP), and a therapeutic peptide (TP) can be preferentially directed to a target site by applying hyperthermia. The compound can be useful for the treatment of tumors.